Postmenopausal bone loss : prevention and replacement

Abstract

Osteoporosis is a skeletal disorder predominantly affecting postmenopausal women. Combination therapy of Carbocalcitonin (Elcatonin) and oral conjugated oestrogens (Premarin) not only prevents postmenopausal bone loss but leads to an increase in bone mass in normal early postmenopausal women. The aims of the study was to investigate the effect of combination therapy. A combination of Elcatonin (Carbo calcitonin) and Premarin was compared to Premarin alone, and to Elcatonin (Carbocalcitonin) alone and all groups were then compared to a control group.